|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2007
|
|
gptkbp:brand
|
gptkb:Lialda
|
|
gptkbp:category
|
B
|
|
gptkbp:class
|
5-aminosalicylic acid derivatives
|
|
gptkbp:clinical_trial
|
NCT00064780
NCT00236066
NCT00319580
NCT00412345
|
|
gptkbp:clinical_use
|
prescription only
|
|
gptkbp:condition
|
gptkb:disease
gptkb:Crohn's_disease
gastrointestinal disorders
|
|
gptkbp:contraindication
|
active gastrointestinal bleeding
severe renal impairment
hypersensitivity to mesalamine
|
|
gptkbp:dosage_form
|
1.2 g
|
|
gptkbp:drug_interactions
|
gptkb:warfarin
gptkb:azathioprine
gptkb:mercaptopurine
|
|
gptkbp:duration
|
up to 12 weeks
long-term maintenance therapy
|
|
gptkbp:effective_date
|
2007-01-01
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
available through healthcare providers
available through pharmacies
available through online resources
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lialda
|
|
gptkbp:indication
|
maintenance of remission in ulcerative colitis
treatment of active ulcerative colitis
|
|
gptkbp:ingredients
|
mesalamine
|
|
gptkbp:label
|
gptkb:Shire_US_Inc.
|
|
gptkbp:lifespan
|
6 to 12 hours
|
|
gptkbp:manufacturer
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
consult healthcare provider
|
|
gptkbp:pharmacokinetics
|
absorbed in the intestine
|
|
gptkbp:previous_name
|
mesalamine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
monitor blood counts
monitor renal function
monitor liver function
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
diarrhea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for effectiveness
|
|
gptkbp:used_for
|
gptkb:ulcerative_colitis
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|